2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular …

S Halvorsen, J Mehilli, S Cassese, TS Hall… - European heart …, 2022 - academic.oup.com
Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations

M Parotto, M Gyöngyösi, K Howe, SN Myatra… - The Lancet …, 2023 - thelancet.com
Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the
acute phase of COVID-19 or emerge after the acute phase, lasting for weeks or months after …

Timing of elective surgery and risk assessment after SARS‐CoV‐2 infection: an update: a multidisciplinary consensus statement on behalf of the Association of …

K El‐Boghdadly, TM Cook, T Goodacre, J Kua… - …, 2022 - Wiley Online Library
The impact of vaccination and new SARS‐CoV‐2 variants on peri‐operative outcomes is
unclear. We aimed to update previously published consensus recommendations on timing …

Involvement of the liver in COVID-19: A systematic review

JC Kariyawasam, U Jayarajah… - … American journal of …, 2022 - pmc.ncbi.nlm.nih.gov
COVID-19, a respiratory viral infection, has affected 388 million individuals worldwide as of
the February 4, 2022. In this review, we have outlined the important liver manifestations of …

Timing of elective surgery and risk assessment after SARS‐CoV‐2 infection: 2023 update: A multidisciplinary consensus statement on behalf of the Association of …

K El‐Boghdadly, TM Cook, T Goodacre, J Kua… - …, 2023 - Wiley Online Library
Guidance for the timing of surgery following SARS‐CoV‐2 infection needed reassessment
given widespread vaccination, less virulent variants, contemporary evidence and a need to …

[HTML][HTML] Efficacy of ivermectin, chloroquine/hydroxychloroquine, and azithromycin in managing COVID-19: A systematic review of phase III clinical trials

NMS Sansone, MN Boschiero, FAL Marson - Biomedicines, 2024 - mdpi.com
Background: During the coronavirus disease (COVID)-19 pandemic several drugs were
used to manage the patients mainly those with a severe phenotype. Potential drugs were …

Is perioperative COVID-19 really associated with worse surgical outcomes? A nationwide COVIDSurg propensity-matched analysis

D Argandykov, A Dorken-Gallastegi… - Journal of Trauma …, 2023 - journals.lww.com
BACKGROUND Patients undergoing surgery with perioperative COVID-19 are suggested to
have worse outcomes, but whether this is COVID-related or due to selection bias remains …

[HTML][HTML] Thromboembolic disease and cardiac thrombotic complication in COVID-19: a systematic review

F Nappi, P Nappi, I Gambardella, SS Avtaar Singh - Metabolites, 2022 - mdpi.com
The coronavirus 2019 pandemic has affected many healthcare systems worldwide. While
acute respiratory distress syndrome (ARDS) has been well-documented in COVID-19, there …

[HTML][HTML] Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines 2023

AN Sumin, DV Duplyakov, FI Belyalov… - Russian Journal of …, 2023 - russjcardiol.elpub.ru
Assessment and modification of cardiovascular risk in non-cardiac surgery. Clinical guidelines
2023 | Sumin | Russian Journal of Cardiology Russian Journal of Cardiology eng | рус User …

Pharmacological treatments for vaccine‐induced immune thrombocytopenia and thrombosis (VITT) after COVID‐19 vaccination

JV Magalhaes, RLG Flumignan… - The Cochrane …, 2024 - pmc.ncbi.nlm.nih.gov
Pharmacological treatments for vaccine‐induced immune thrombocytopenia and
thrombosis (VITT) after COVID‐19 vaccination - PMC Skip to main content Here's how you …